Business Context and Reporting Period
This Form 8-K filing by Savara Inc. (SVRA) reports on events occurring on March 31, 2020. The primary event is the satisfaction of the final condition precedent for a License and Collaboration Agreement with Grifols, S.A., which became effective on this date. The agreement grants Savara an exclusive, worldwide license to commercialize pharmaceutical preparations containing ciprofloxacin in a liposomal formulation.
Key Financial Metrics and Transaction Terms
The filing details the consideration paid to Grifols for the license rights, which includes both cash and equity components:
- Upfront Cash Payment: $3,247,000
- Upfront Equity Payment: 1,000,000 shares of Savara common stock (Consideration Shares)
- Milestone Payments: Obligations exist for FDA and EMA approvals, as well as sales milestones based on annual global net sales thresholds.
- Royalties: Tiered, low double-digit royalties on annual global net sales, subject to reduction if competing inhaled ciprofloxacin products enter the market.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period, as this is a current report focused on a material agreement rather than a periodic financial statement.
Material Changes and Operational Obligations
Effective March 31, 2020, Savara assumed sole responsibility for the development, regulatory, and commercialization activities and costs for the Licensed Products. Key obligations include:
- Conducting a Phase 3 clinical trial for the Initial Indication (non-cystic fibrosis bronchiectasis or associated pulmonary infections).
- Using "Diligent Efforts" to obtain regulatory approval in the U.S. and E.U.
- Maintaining material funds, full-time equivalents, and resources for 12 consecutive months to avoid termination by Grifols.
Outlook, Risks, and Contingencies
Termination Risks: Grifols may terminate the license immediately if Savara challenges a Grifols Patent or fails to allocate necessary resources for development for 12 consecutive months. Either party may terminate for material breach or insolvency.
Unregistered Securities: The issuance of 1,000,000 Consideration Shares to Grifols was made pursuant to Section 4(a)(2) of the Securities Act of 1933 and has not been registered. These shares may not be offered or sold in the U.S. absent registration or an exemption.
Future Filings: The full text of the License Agreement is not included in this filing but is planned to be filed with Savara's Form 10-Q for the quarter ended March 31, 2020.
Investor Verification Checklist
- Verify the impact of the $3.247 million cash outflow and 1,000,000 share issuance on Savara's current liquidity and dilution.
- Review the upcoming Form 10-Q for the full text of the License Agreement to understand specific milestone thresholds and royalty reduction triggers.
- Monitor the allocation of funds and resources to ensure compliance with the 12-month development requirement to prevent immediate termination.
- Assess the competitive landscape for inhaled ciprofloxacin products, as the entry of a competitor could reduce royalty obligations.